Elixir Clinical Research

May 20-23, 2021, Suzhou

With the breeze on the shore of Jinji Lake, the 2021 DIA China Annual Meeting was concluded successfully. The meeting attracted thousands of industry colleagues under the theme of "Integrating into Globalization, Departing with Innovation", which not only delivered an academic feast for the participants and showed them the innovation and development of biopharmaceutical industry in China, but also shared some insights with them on how industry innovation could go global.

01. Wonderful enterprise display & hot consultation on site

During the three-day exhibition, business experts of Elixir Clinical Research brought targeted innovative clinical solutions to clients and partners, attracting many new and existing clients to stop by for consultation and business negotiation.

Elixir Clinical Research's full service information management and operation model, driven by data and connecting with all parties involved in clinical study, can not only improve the speed of whole clinical study process, but also achieve accurate prediction, risk prevention and quality control during the project.

02. Academic sharing & discussion

In the afternoon of May 22, Jun Li, Director of Regulatory Affairs of Elixir Clinical Research, along with experts from DIA China's Regulatory Affairs Community (RAC), presented the hot topic - "The Role of RA in the Whole Life Cycle Management of Pharmaceuticals" and released the second edition of the blue paper Provisions for Drug Registration.

During the sharing session, Mr. Li mainly focused on the management of changes being part of the whole life cycle management of drugs in clinical registration studies and post-marketing.

03. Creative gifts drew huge attentions

Elixir Clinical Research reminded every friend to take care during busy clinical trials. Besides, warm sleep lamps prepared by Elixir Family for the exhibition were much loved.

Great thanks go to each and every one of industry colleagues for your presence, and your support and attention to Elixir Clinical Research.

Look forward to 2022 DIA!